AKR101
Chronic Wounds (e.g., venous leg ulcers, diabetic foot ulcers)
Pre-clinicalActive
Key Facts
Indication
Chronic Wounds (e.g., venous leg ulcers, diabetic foot ulcers)
Phase
Pre-clinical
Status
Active
Company
About Akribes Biomedical
Akribes Biomedical is a private, preclinical-stage biotech targeting the chronic wound market, a costly and underserved area with no new drugs in over 15 years. The company's core innovation is a patient-derived assay platform that enables the identification of novel compounds and personalized treatment matching. Led by seasoned ex-Novartis executives, Akribes is developing its lead compound, AKR101, which has shown superior activity in its proprietary models, positioning it to potentially disrupt the standard of care.
View full company profileTherapeutic Areas
Other Chronic Wounds (e.g., venous leg ulcers, diabetic foot ulcers) Drugs
| Drug | Company | Phase |
|---|---|---|
| Aurase Wound Gel | SolasCure | Phase 2 |